Drug Trial Radar · NCT01807949
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
Last checked: Nov 19, 2026Latest source record: Sep 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
563
Actual
Start
Apr 2013
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Mar 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.
Conditions
- Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions
PlaceboDrug
Matching placebo tablet
Lumacaftor Plus Ivacaftor CombinationDrug
Fixed dose combination tablet
IvacaftorDrug
Film-coated tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline, Week 16 and 24
Locations
82 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Oakland, California
Site not named
Sacramento, California
Site not named
Aurora, Colorado
Site not named
Hartford, Connecticut
Site not named
New Haven, Connecticut
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Kansas City, Kansas
Site not named
Lexington, Kentucky
Site not named
Portland, Maine
Site not named
Worcester, Massachusetts
Site not named
Detroit, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Jackson, Mississippi
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Morristown, New Jersey
Site not named
New Brunswick, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Toledo, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Sioux Falls, South Dakota
Site not named
Memphis, Tennessee
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.